WO2019123294A3 - Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus - Google Patents

Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus Download PDF

Info

Publication number
WO2019123294A3
WO2019123294A3 PCT/IB2018/060309 IB2018060309W WO2019123294A3 WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3 IB 2018060309 W IB2018060309 W IB 2018060309W WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
treatment
lupus erythematosus
systemic lupus
pyrimidine derivatives
Prior art date
Application number
PCT/IB2018/060309
Other languages
French (fr)
Other versions
WO2019123294A2 (en
Inventor
Jonathan DEANE
Tobias Junt
Pius Loetscher
Barbara Nuesslein-Hildesheim
Ben Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to JP2020533229A priority Critical patent/JP2021507889A/en
Priority to CN201880078211.3A priority patent/CN111432818A/en
Publication of WO2019123294A2 publication Critical patent/WO2019123294A2/en
Publication of WO2019123294A3 publication Critical patent/WO2019123294A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to the use of certain pyrazolo piperidine derivatives in the treatment of diseases and conditions associated with the interaction of the toll like receptor. More particularly, the said treatment pertains to the treatment of NPSLE.
PCT/IB2018/060309 2017-12-22 2018-12-19 Novel uses of pyrazolo piperidine derivatives WO2019123294A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2020533229A JP2021507889A (en) 2017-12-22 2018-12-19 New use of pyrazolopiperidine derivatives
CN201880078211.3A CN111432818A (en) 2017-12-22 2018-12-19 Pyrazolopiperidine and pyrazolopyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17210059 2017-12-22
EP17210059.6 2017-12-22
US201862769635P 2018-11-20 2018-11-20
US62/769,635 2018-11-20

Publications (2)

Publication Number Publication Date
WO2019123294A2 WO2019123294A2 (en) 2019-06-27
WO2019123294A3 true WO2019123294A3 (en) 2019-08-01

Family

ID=65201642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060309 WO2019123294A2 (en) 2017-12-22 2018-12-19 Novel uses of pyrazolo piperidine derivatives

Country Status (3)

Country Link
JP (1) JP2021507889A (en)
CN (1) CN111432818A (en)
WO (1) WO2019123294A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155042A1 (en) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
TW202016105A (en) 2018-06-12 2020-05-01 瑞士商赫孚孟拉羅股份公司 Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
WO2020020800A1 (en) 2018-07-23 2020-01-30 F. Hoffmann-La Roche Ag Novel piperazine compounds for the treatment of autoimmune disease
CN112638908A (en) 2018-09-04 2021-04-09 豪夫迈·罗氏有限公司 Benzothiazoles for treatment of autoimmune diseases
EP3847170B1 (en) 2018-09-06 2022-06-22 F. Hoffmann-La Roche AG Novel cyclic amidine compounds for the treatment of autoimmune disease
AU2022257039A1 (en) 2021-04-16 2023-10-05 Gilead Sciences, Inc. Thienopyrrole compounds
KR20240056747A (en) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 Thienopyrrole compounds
WO2023135505A1 (en) * 2022-01-11 2023-07-20 Novartis Ag Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (en) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2018047081A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
KR101865120B1 (en) 2016-06-29 2018-06-08 숭실대학교 산학협력단 Wireless positioning method based on test node and apparatus thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (en) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2018047081A1 (en) * 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLISON R. BIALAS ET AL: "Microglia-dependent synapse loss in type I interferon-mediated lupus", NATURE, 14 June 2017 (2017-06-14), GB, XP055476303, ISSN: 0028-0836, DOI: 10.1038/nature22821 *
CÉSAR MAGRO-CHECA ET AL: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives", DRUGS, vol. 76, no. 4, 26 January 2016 (2016-01-26), NZ, pages 459 - 483, XP055476422, ISSN: 0012-6667, DOI: 10.1007/s40265-015-0534-3 *
WANG H P ET AL: "Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 607, no. 1-3, 1 April 2009 (2009-04-01), pages 102 - 106, XP026007773, ISSN: 0014-2999, [retrieved on 20090304], DOI: 10.1016/J.EJPHAR.2009.02.039 *

Also Published As

Publication number Publication date
JP2021507889A (en) 2021-02-25
WO2019123294A2 (en) 2019-06-27
CN111432818A (en) 2020-07-17

Similar Documents

Publication Publication Date Title
WO2019123294A3 (en) Pyrazolo piperidine and pyrazolo pyrimidine derivatives for the treatment of neuropsychiatric systemic lupus erythematosus
WO2017201132A3 (en) Pyrrolobenzodiazepines and conjugates thereof
IL246564A (en) 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
EP3481831A4 (en) NOVEL 4-AMINOPYRAZOLO[3,4-d]PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
CL2015003444A1 (en) Compounds of 3,4 dihydroisoquinolin-2 (1h) -yl
WO2018067520A3 (en) Therapeutic agents and methods:
WO2017214170A3 (en) Baff-r antibodies and uses thereof
EP3675860A4 (en) Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
EP3765521A4 (en) Anti-folate receptor 1 antibodies and uses thereof
SG11201703416WA (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3762386A4 (en) Adenosine receptor antagonists and uses thereof
EP3660019C0 (en) 7h-pyrazolo[3,4-d]triazine-2-oxides as explosives
WO2015195863A8 (en) Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
IL267801B1 (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
EP3730492A4 (en) Substituted pyrazolo[1,5-a]pyrimidine compound and pharmaceutical composition and use thereof
EP3715344A4 (en) 1,4-benzodiazapin-2-one derivatives and use thereof
IL262711A (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
EP3653614A4 (en) Tetrahydronaphtho[1,2-b]furan-2(3h)-one derivative and preparation and use thereof in pharmaceuticals
WO2018013951A9 (en) Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EP3546458A4 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
IT201600130012A1 (en) Composition for use in the treatment of disorders of the urogenital system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020533229

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2